Jade Biosciences (JBIO) EBT (2020 - 2026)

Jade Biosciences has reported EBT for 7 years, with the latest figure at -$40.4 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 5.72% year-over-year to -$40.4 million; the trailing twelve-month figure through Mar 2026 stood at -$123.3 million (down 22.95% YoY), and the FY2025 full-year result was $236000.0, up 100.34% from the prior year.
• EBT for Q1 2026 stood at -$40.4 million, down from -$31.9 million in the prior quarter.
• The five-year high for EBT was $45.2 million in Q4 2023, with the low at -$47.0 million in Q4 2024.
• Historically, EBT has averaged -$15.6 million across 5 years, with a median of -$19.0 million in 2023.
• Annual changes were most pronounced in 2022 — EBT jumped 434.4% — and 2025, when it plunged 4254.03%.
• Jade Biosciences' EBT stood at $27.5 million in 2022, then soared by 64.51% to $45.2 million in 2023, then tumbled by 203.89% to -$47.0 million in 2024, then soared by 32.11% to -$31.9 million in 2025, then dropped by 26.52% to -$40.4 million in 2026.
• The last three EBT figures came in at -$40.4 million (Q1 2026), -$31.9 million (Q4 2025), and -$25.1 million (Q3 2025), per Business Quant data.